Finch Therapeutics (US:FNCH)2022-12-02 14:17CP101 for Recurrent C difficile Infection (CDI) - CDI is a debilitating disease with a significant economic impact, costing over $5 billion annually in the U S [9] - CP101 achieved a 33 8% relative risk reduction for CDI recurrence through Week 8 in the PRISM3 trial [13] - In a post-hoc analysis of PRISM3 and PRISM-EXT, 88 2% of participants were without CDI recurrence through 8 weeks following last dose of CP101 [17] - Clinical safety data for CP101 are promising, with treatment-related adverse events primarily gastrointestinal in nature and no treatment-related serious adverse events (SAEs) [18] - PRISM4, a Phase 3 trial of CP101 in recurrent CDI, has topline P4 Week 24 readout expected in H1 2024 [6, 24] Microbiome Therapeutics and Pipeline - Microbiome therapeutics have the potential to be a transformative new class of medicines [5] - Humans carry over 20 million microbial genes, compared to approximately 20 thousand human genes [5] - Finch aims to harness the full diversity and potential of the microbiome, with additional assets targeting autism and IBD [6] - Finch is exploring opportunities to further the development of FIN-524 for UC and FIN-525 for Crohn's disease through a potential strategic partnership [34] Autism Spectrum Disorder (ASD) - Open label data shows improvements in both GI and behavioral symptoms following microbiota transplantation (n=18) [39] - Randomized clinical study showed improvement in both GI and behavioral symptoms following microbiota transplantation (n=45) [41] - In the randomized clinical study, behavioral scores significantly improved at 2 months post microbiota transplantation by 10 8% [42]